Emanuel, Robyn M, Dueck, Amylou C, Geyer, Holly L, Kiladjian, Jean-Jacques, Slot, Stefanie, Zweegman, Sonja, Te Boekhorst, Peter A W, Commandeur, Suzan, Schouten, Harry C, Sackmann, Federico, Kerguelen Fuentes, Ana, Hernández-Maraver, Dolores, Pahl, Heike L, Griesshammer, Martin, Stegelmann, Frank, Doehner, Konstanze, Lehmann, Thomas, Bonatz, Karin, Reiter, Andreas, Boyer, Francoise, Etienne, Gabriel, Ianotto, Jean-Christophe, Ranta, Dana, Roy, Lydia, Cahn, Jean-Yves, Harrison, Claire N, Radia, Deepti, Muxi, Pablo, Maldonado, Norman, Besses, Carlos, Cervantes, Francisco, Johansson, Peter L, Barbui, Tiziano, Barosi, Giovanni, Vannucchi, Alessandro M, Passamonti, Francesco, Andreasson, Bjorn, Ferrari, Maria L, Ferarri, Maria L, Rambaldi, Alessandro, Samuelsson, Jan, Birgegard, Gunnar, Tefferi, Ayalew, Mesa, Ruben A, Interne Geneeskunde, RS: GROW - School for Oncology and Reproduction, Service d'hématologie clinique [Avicenne], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Université Paris 13 (UP13)-Hôpital Avicenne [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Paleontology section, Transvaal Museum, Département d'Hématologie, Institut de Cancéro-hématologie, Hôpital Morvan [Brest], Service d'Hematologie et Médecine Interne, Centre Hospitalier Régional Universitaire de Nancy (CHRU Nancy), CIC - Poitiers, Université de Poitiers-Centre hospitalier universitaire de Poitiers (CHU Poitiers)-Direction Générale de l'Organisation des Soins (DGOS)-Institut National de la Santé et de la Recherche Médicale (INSERM), TheREx, Techniques de l'Ingénierie Médicale et de la Complexité - Informatique, Mathématiques et Applications, Grenoble - UMR 5525 (TIMC-IMAG), VetAgro Sup - Institut national d'enseignement supérieur et de recherche en alimentation, santé animale, sciences agronomiques et de l'environnement (VAS)-Institut polytechnique de Grenoble - Grenoble Institute of Technology (Grenoble INP )-Centre National de la Recherche Scientifique (CNRS)-Université Joseph Fourier - Grenoble 1 (UJF)-VetAgro Sup - Institut national d'enseignement supérieur et de recherche en alimentation, santé animale, sciences agronomiques et de l'environnement (VAS)-Institut polytechnique de Grenoble - Grenoble Institute of Technology (Grenoble INP )-Centre National de la Recherche Scientifique (CNRS)-Université Joseph Fourier - Grenoble 1 (UJF), Hematology, Ospedali Riuniti, Department of Oncology and Hematology, Università degli Studi di Modena e Reggio Emilia (UNIMORE), Department of Haematology, Division of Medicine, Institution for Medical Sciences, University Hospital, and CCA - Innovative therapy
Purpose Myeloproliferative neoplasm (MPN) symptoms are troublesome to patients, and alleviation of this burden represents a paramount treatment objective in the development of MPN-directed therapies. We aimed to assess the utility of an abbreviated symptom score for the most pertinent and representative MPN symptoms for subsequent serial use in assessing response to therapy. Patients and Methods The Myeloproliferative Neoplasm Symptom Assessment Form total symptom score (MPN-SAF TSS) was calculated as the mean score for 10 items from two previously validated scoring systems. Questions focus on fatigue, concentration, early satiety, inactivity, night sweats, itching, bone pain, abdominal discomfort, weight loss, and fevers. Results MPN-SAF TSS was calculable for 1,408 of 1,433 patients with MPNs who had a mean score of 21.2 (standard deviation [SD], 16.3). MPN-SAF TSS results significantly differed among MPN disease subtypes (P < .001), with a mean of 18.7 (SD, 15.3), 21.8 (SD, 16.3), and 25.3 (SD, 17.2) for patients with essential thrombocythemia, polycythemia vera, and myelofibrosis, respectively. The MPN-SAF TSS strongly correlated with overall quality of life (QOL; r = 0.59; P < .001) and European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC QLQ-C30) functional scales (all P < .001 and absolute r ≥ 0.50 except social functioning r = 0.48). No significant trends were present when comparing therapy subgroups. The MPN-SAF TSS had excellent internal consistency (Cronbach's α = .83). Factor analysis identified a single underlying construct, indicating that the MPN-SAF TSS is an appropriate, unified scoring method. Conclusion The MPN-SAF TSS is a concise, valid, and accurate assessment of MPN symptom burden with demonstrated clinical utility in the largest prospective MPN symptom study to date. This new prospective scoring method may be used to assess MPN symptom burden in both clinical practice and trial settings.